{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:40:58Z","timestamp":1792536058926,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmogo.2026.100411","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:37:12Z","timestamp":1788284232000},"page":"100411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR\/MSI-H gastrointestinal tumors treated with pembrolizumab"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0408-6871","authenticated-orcid":false,"given":"N.","family":"Mart\u00ednez Lago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"S\u00e1nchez Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carral Maseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rez Martelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3360-3070","authenticated-orcid":false,"given":"M.","family":"Covela R\u00faa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-5830","authenticated-orcid":false,"given":"A.","family":"Fern\u00e1ndez Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de la C\u00e1mara G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gonz\u00e1lez Villarroel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reboredo L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Pad\u00edn Iruegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Abdulkader Nallib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmogo.2026.100411_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100411_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmogo.2026.100411_bib3","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100411_bib4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jamaoncol.2018.4942","article-title":"Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status","volume":"5","author":"Cohen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100411_bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100411_bib6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.esmogo.2026.100411_bib7","first-page":"4053","article-title":"Relationship between MLH1 promoter methylation, RAS\/BRAF mutations, and response to immune checkpoint inhibitors in patients with advanced colorectal cancer","volume":"26","author":"Salem","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.esmogo.2026.100411_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nbt.3966","article-title":"Analysis of somatic microsatellite indels identifies driver events in human tumors","volume":"35","author":"Maruvka","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.esmogo.2026.100411_bib9","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmogo.2026.100411_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115338","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer","volume":"220","author":"Qi","year":"2025","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100411_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmogo.2026.100411_bib12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2026.100411_bib13","article-title":"Prognostic impact of clinical factors in MSI-H\/dMMR gastrointestinal tumors treated with immune checkpoint inhibitors: results from a multicenter real-world study","volume":"11","author":"Mart\u00ednez-Lago","year":"2026","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.esmogo.2026.100411_bib14","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.3390\/cancers15205090","article-title":"Unraveling resistance to immunotherapy in MSI-high colorectal cancer","volume":"15","author":"Heregger","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmogo.2026.100411_bib15","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-17-1327","article-title":"Genetic mechanisms of mmune evasion in colorectal cancer","volume":"8","author":"Grasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmogo.2026.100411_bib16","doi-asserted-by":"crossref","first-page":"888181","DOI":"10.3389\/fonc.2022.888181","article-title":"Microsatellite instability and metastatic colorectal cancer: a clinical perspective","volume":"12","author":"Buchler","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100411_bib17","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3390\/ijms26051988","article-title":"Mechanisms and strategies to overcome drug resistance in colorectal cancer","volume":"26","author":"Haynes","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826001111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826001111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:36:35Z","timestamp":1792535795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826001111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":17,"alternative-id":["S2949819826001111"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100411","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR\/MSI-H gastrointestinal tumors treated with pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100411"}}